Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 10Breast Neoplasms 9Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Adenomatous Polyposis Coli 4Sarcoma 3Glioblastoma 3Central Nervous System Neoplasms 3Paranasal Sinus Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Breast Carcinoma In Situ 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Stomatitis 1Smoldering Multiple Myeloma 1Smoking 1Recurrence 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Precancerous Conditions 1

Interventions

mirabegron 1Leuprolide 1Doxazosin 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lower Urinary Tract Symptoms × Celecoxib × Clear all
NCT01678313 2014-07-15

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

Buddhist Tzu Chi General Hospital

Phase 2 Completed
140 enrolled 10 charts
Genitourinary

Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡